Antimicrobial stewardship initiatives: A programmatic approach to optimizing antimicrobial use

Antibiotic Optimization: Concepts and Strategies in Clinical Practice

Volumn , Issue , 2004, Pages 261-326

  Fraser, Gilles L ^a,b   Stogsdill, Patricia ^a,b   Owens, Robert C ^a,b  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84982805768     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (101)

1. Schlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18:275–91.
2. Bell D. Development of the Public Health Action Plan to Combat Antimicrobial Resistance, in The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment-Workshop Summary Knobler SL, Lemon SM, Najafi M, Burroughs T, Eds Forum on Emerging Infections. Washington, DC: National Academy Press, 2003.
3. Department of Health NHS Executive. UK Antimicrobial Resistance Strategy and Action Plan, Crown Publishing, National Academy Press, June 2000.
4. Knox K, Lawson W, Dean B, Holmes A. Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist—a UK perspective J Hosp Infection; 2003; 53: 85–90.
5. Mohammed JM, Weigel L, Clark N, McDougal L, Raney P, Whitney A, McAllister S, Kellum M, Jevitt L, Tenover FC. High-level vancomycin resistance in a clinical isolate of Staphylococcus aureus. Abstract LB-7. Program and abstracts of the, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2002, San Diego, California.
6. Paterson DL, Huejer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, Bonomo RA. Extended-spectrum beta-lactamases in bloodstream isolates worldwide: Dominance of SHV type beta- lactamases and worldwide prevalence of CTX-M type enzymes. Abstract C2-1833. Program and abstracts of the, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2002, San Diego, California.
7. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units JAMA; 2003; 289:885–888.
8. Gerding DN. The search for good antimicrobial stewardship Jt Comm J Qual Improv; 2001; 27:403–4.
9. Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP Jr, Prato BS. Antibiotic optimization, an evaluation of patient safety and economic outcomes Arch Intern Med; 1997; 157:1689–1694.
10. Gross R, Morgan AS, Kinky DE. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes Clin Infect Dis; 2001; 33:289–295.
11. Camins BC, Wells JB, Googe HL. The impact of an antibiotic utilization program on antibiotic use in a teaching hospital- A randomized trial. Abstract 489. Program and abstracts of the, 41st Infectious Diseases Society of America Meeting, October 9–12, 2003, San Diego, California.
12. Srinivasan A, Patel A, Song X. Cost reductions in antimicrobial expenditures following implementation of a comprehensive antimcirobial management program. Abstract 488. Program and abstracts of the, 41st Infectious Diseases Society of America Meeting, October 9–12, 2003, San Diego, California.
13. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures susceptibilities, and clinical outcomes Clin Infect Dis; 1997; 25:230–239.
14. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, Lim M. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA; 1998; 280: 1233–1237.
15. Schiff GD, Wisniewski M, Bult J, Parada JP, Aggarwal H, Schwartz DN. Improving inpatient antibiotic prescribing J Qual Improvement; 2001; 27:387–402.
16. Avorn J, Solomon DH. Cultural and economic factors that (MIS) shape antibiotic use: the nonpharmacologic basis of therapeutics Ann Intern Med; 2000; 133:128–135.
17. Wenzel RP, Edmond MB. Multidrug-resistant Streptococcus pneumoniae N Engl J Med; 2001; 344:1331.
18. Glowacki RG, Schwartz DN, Itokazu GS, Wisniewski MF, Kieszkowski P, Weinstein RA. Antibiotic combinations with redundant antimicrobial spectra: clinical epidemiology and pilot intervention of computer-assisted surveillance Clin Infect Dis; 2003; 37:59–64.
19. McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol; 1994; 15:478–483.
20. Phillips I. Prudent use of antibiotics: are our expectations justified? Clin Infect Dis; 2001; 23(Suppl 3):S130-S132.
21. Moberg CL. Rene Duos: A harbinger of microbial resistance to antibiotics Microbial Drug Resistance; 1996; 2:287–297.
22. Levy SB, Fitzgerald GG, Macone AB. Changes in the intestinal flora of farm personnel after introduction of tetracycline- supplemented feed on a farm N Engl J Med; 1976; 295:583–588.
23. Bell DM. Promoting appropriate antimicrobial drug use: perspective from the Centers for Disease Control and Prevention Clin Infect Dis; 2001; 33(Suppl 3):S245-S250.
24. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use Rev Infect Dis; 1983; 5: 1033–1048.
25. Dowell SF, Scwartz B. Resistant pneumococci: protecting patients through judicious antibiotic use Am Fam Physician; 1997; 55:1647–1654.
26. Scwartz B. Preventing the spread of antimicrobial resistance among bacterial respiratory tract pathogens in industrialized countries: the case for judicious antimicrobial use Clin Infect Dis; 1999; 28:211–213.
27. Diekema DJ, BootsMiller BJ, Vaughn TE. Antimicrobial resistance trends and outbreak frequency in United States hospitals Clin Infect Dis; 2004; 38:78–85.
28. Tenover FC, Weigel LM, Appelbaum PC. Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania Antimicrob Agents Chemother.; 2004; 48:275–280.
29. Lautenbach E, Strom BL, Nachamkin I, Bilker WB, Marr AM, Larosa LA, Fishman NO. Longitudinal trends in fluoroquinolone resistance among enterobacteriaceae isolates from inpatients and outpatients, 1989–2000: differences in the emergence of resistance and epidemiology of resistance across organisms Clin Infect Dis; 2004; 38:655–662.
30. Chen DK, McGeer A, DeAzavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada N Engl J Med; 1999; 341:233–239.
31. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae: Report from the ARREST program. Abstract K-1397. Program and abstracts of the, 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14–17, 2003, Chicago, Illinois.
32. Leibovici L, Berger R, Gruenewald T, Yahav J, Yehezkelli Y, Milo G, Paul M, Samra Z, Pitlik SD. Departmental consumption of antibiotic drugs and subsequent resistance: A quantitative link J Antimicrob Chemother; 2001; 48:535–540.
33. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis Antimicrob Agents Chemother; 1998; 42:2966–2972.
34. Bernard L, Vaudaux P, Vuagnat A, Stern R, Rohner P, Pittet D, Schrenzel J, Hoffmeyer P, Hoffmeyer P. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin- resistant Staphylococcus aureus: lack of emergence of glyco- peptide resistance Infect Control Hosp Epidemiol; 2003; 24: 650–54.
35. Pitout JDD, Sanders CS, Sanders WE. Antimicrobial resistance with focus on beta lactam resistance in gram-negative bacilli Am J Med; 1997; 103:51–59.
36. DiGiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit Am J Respir Crit Care Med; 1999; 160:976–981.
37. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes Clin Infect Dis; 2003; 36:1433–1437.
38. Classen DC, Pestonik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients JAMA; 1991; 266:2847–2851.
39. Ebbesen J, Buajordet I, Erikssen J, Brors O, Hilberg T, Svaar H, Sandvik L. Drug-related deaths in a department of internal medicine Arch Intern Med; 2001; 161:2317–2323.
40. Petrak RM, Sexton DJ, Butera ML, Tenenbaum MJ, MacGregor MC, Schmidt ME, Joseph WP, Kemmerly SA, Dougherty MJ, Bakken JS, Curfman MF, Martinelli LP, Gainer RB. The value of an infectious disease specialist Clin Infect Dis; 2003; 36:1013–1017.
41. Projan SJ. Why is big pharma getting out of antibacterial drug discovery Curr Opin Microbiol; 2003; 6:427–430.
42. Besser RE. Antimicrobial prescribing in the United States: good news, bad news Ann Intern Med; 2003; 138:605–606.
43. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991–1999 Ann Intern Med; 2003; 138:525–533.
44. Zeigler MG, Lew P, Singer BC. Inaccuracy of drug information from pharmaceutical sales representatives JAMA; 1995; 273: 1296–1298.
45. Billstein SA. How the pharmaceutical industry brings an antibiotic drug to market in the United States Antimicrob Ag Chemother; 1994; 38:2679–2682.
46. Greco PJ, Eisenberg JM. Changing physicians’ practices N Engl J Med; 1993; 329:1271–1274.
47. Davis DA, Thomason MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies JAMA; 1995; 274: 700–705.
48. Fraser GL, Wennberg DE, Dickens JD Jr, Lambrew CT. Changing physician behavior in ordering digoxin assays Ann Pharmacother; 1996; 30:449–454.
49. Keller RB, Soule DN, Wennberg JE, Hanley DF. Dealing with geographic variations in the use of hospitals: the experience of the Maine Medical Assessment Foundation Orthopedic Study Group J Bone Joint Surg; 1990; 72A:1286–1293.
50. Soumerai SB, Avorn J. Principles of educational outreach (academic detailing) to improve clinical decision making JAMA; 1991; 263:549–556.
51. Garibaldi RA. Computers and the quality of care—a clinician’s perspective N Engl J Med; 1998; 338:259–260.
52. Morris AH. Developing and implementing computerized protocols for standardization of clinical decisions Ann Intern Med; 2000; 132:373–383.
53. James BC. Making it easy to do it right N Engl J Med; 2001; 345:991–992.
54. Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW. Effects of computerized physician order entry on prescribing practices Arch Intern Med; 2002; 160:2741–2747.
55. Fraser GL, Dickens JD, Wennberg DE. Changing Physician Digoxin Assay Ordering Behavior; a Five-Year Follow-up Study P&T; 1997; 22:385–392.
56. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital Clin Infect Dis; 1997; 24:471–485.
57. Bantar C, Sartori B, Vesco E, Heft C, Saul M, Salamone F, Oliva ME. A hospitalwide intervention program to optimize the quality of antibiotic use: Impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance Clin Infect Dis; 2003; 37:180–186.
58. Stogsdill P, Claffey T, Bates P. Antimicrobial Stewardship Program: From Research to Practice [Abstract 583]. In: Program and abstracts of the, 40th Infectious Diseases Society of America Meeting, October 24–27, 2003, Chicago, IL.
59. Modjtabai K, Prato BS, Stogsdill PB, Owens RC Jr. Impact of inpatient prescribing changes on antimicrobial susceptibilities: A five-year longitudinal study [Abstract 156]. In: Program and abstracts of the, 41st Infectious Diseases Society of America Meeting, October 9–12, 2003, San Diego, California.
60. Ruttimann S, Keck B, Hartmeier C, Maetzel A, Bucher HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital Clin Infect Dis; 2004; 38:348–356.
61. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years Infect Control Hosp Epidemiol; 2003; 24:699–706.
62. LaRocco A Jr. Concurrent antibiotic review programs—A role for infectious diseases specialists at small community hospitals Clin Infect Dis; 2003; 37:742–743.
63. Gentry CA, Greenfield RA, Slater LN, Slater LN, Wack M, Huycke MM. Outcomes of an antimicrobial control program in a teaching hospital Am J Health-Syst Pharm; 2000; 57: 268–274.
64. Carling PC, Fung T, Coldiron JS. Parenteral antibiotic use in acute-care hospitals: a standardized analysis of fourteen institutions Clin Infect Dis; 1999; 29:1189–1196.
65. Briceland LL, Nightingale CH, Quintiliani RQ, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach Arch Intern Med; 1988; 148:2019–2022.
66. Mandell GL, Bennett JE, Dolin R, Eds. New York: Churchill Livingstone, 1995.
67. Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to Antimicrobial Therapy, 2002. Hyde Park Vermont.
68. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients Clin Infect Dis; 2002; 34: 340–345.
69. Ambrose PG, Owens RC Jr. New antibiotics in pulmonary and critical care medicine: focus on advanced generation quino- lones and cephalosporins Seminars Resp Crit Care Med; 2000; 21:19–32.
70. Rice LB. Controlling antibiotic resistance in the ICU: Different bacteria, different strategies Cleveland Clinic J Med; 2003; 70:793–800.
71. Fraser GL. Antibiotic optimization: what are the costs associated with saving money? Pharmacoeconomics: Infectious Diseases 1997; 1:2–4.
72. Madaras-Kelly K. Optimizing antibiotic use in hospitals: the role of population-based antibiotic surveillance in limiting antibiotic resistance Pharmacotherapy; 2003; 23:1627–1633.
73. Ansari F, Gray K, Nathwani D, Phillips G, Ogston S, Ramsay C, Davey P. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis J Antimicrob Chemother; 2003; 52:842–848.
74. Ramsay C, Brown E, Hartman E, Davey P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing J Anti- microb Chemother; 2003; 52:764–771.
75. The Cochrane Effective Practice and Organization of Care Group (EPOC). The Data Collection Checklist. Cochrane Effective Practice and Organization of Care Group (EPOC) Methods Papers [Online.] 2002. http://www.epoc.uottawa.ca/ (accessed 14 March 2004).
76. Owens RC Jr., Bates P, Lerwick P. Effect of community-acquired pneumonia guidelines on discharge efficiency and initial antibiotic choices [Abstract 556]. Program and abstracts of the, 40th Infectious Diseases Society of America Meeting, October 24–27, 2002, Chicago, IL.
77. Vinken A, Li Z, Banan D, Rittenhouse B, Wilike R, Nathwani D. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model J Hosp Infect; 2001; 49(Suppl A): S13-S24.
78. Pakyz A, Scheld WM, Schlag K. Evaluation of an antimicrobial surveillance team (AST) program after a three-year period. In Program and Abstracts of the, 39th Annual Infectious Diseases Society of America Meeting [abstract no. 810], October 25–28, 2001, Chicago, IL.
79. Calfee DP, Brooks J, Zirk NM, Giannetta ET, Scheld WM, Farr BM. A pseudo-outbreak of nosocomial infections associated with the introduction of an antibiotic management programme J Hosp Infect; 2003; 55:26–32.
80. Solomon DH, Van Houten L, Glynn RJ, Baden L, Curtis K, Schrager H, Avorn J. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center Arch Intern Med; 2001; 161:1897–1902.
81. Ambrose PG, Owens RC Jr, Grasela D. Antimicrobial Pharmacodynamics Medical Clinics North America; 2000; 84: 1431–1445.
82. Goldberg J, Owens RC Jr. Optimizing antimicrobial dosing in the critically ill patient Curr Opin Crit Care; 2002; 8:435–440.
83. Melmon KL, Blaschke TF. The undereducated physician’s therapeutic decisions N Engl J Med; 1983; 308:1473–1474.
84. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach N Engl J Med; 1983; 308;:1457–1463.
85. http://www.leapfroggroup.org accessed 5/30/03.
86. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor Ann Pharma- cother; 1999; 33:1026–1031.
87. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes Ann Intern Med; 1996; 124:884–890.
88. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, Lloyd JF, Burke JP. A computer-assisted management program for antibiotics and other antiinfective agents N Engl J Med; 1998; 338:232–238.
89. Lesar TS, Briceland LL. Survey of antibiotic control policies in university-affiliated teaching institutions Ann Pharmacother; 1996; 30:31–34.
90. Frank MO, Batteiger BE, Sorensen SJ, Hartstein AI, Carr JA, McComb JS, Clark CD, Abel SR, Mikuta JM, Jones RB. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program Clinical Performance and Quality Health Care; 1997; 5:180–188.
91. Himmelgerg CJ, Pleasants RA, Weber DJ, Kessler JM, Samsa GP, Spivey JM, Morris TL. Use of antimicrobial drugs in adults before and after removal of a restriction policy Am J Hosp Pharm; 1991; 48:1220–1227.
92. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical Pharmacodynamics of Quinolones Infect Dis Clinics North America; 2003; 17:529–543.
93. Ambrose PG, Owens RC Jr, Russo R, Zoe-Powers A, Jones DT. Utilizing Pharmacodynamics in Formulary and Clinical Decision-Making. In: Nightingale CH, Murakawa T, Ambrose PG, Eds Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker Publishers, 2001: 385–408.
94. Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN. Pharmacodynamic Considerations in the Treatment of Moderate to Severe Pseudomonal Infections with Cefepime J Antimicrob Chemother; 2002; 49:445–453.
95. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones Infect Dis Clin N Am; 2003; 17:529–543.
96. Avorn J, Soumerai J, Taylor W, Wessels MR, Janousek J, Weiner M. Reduction of incorrect antibiotic dosing through a structured educational order form Arch Intern Med; 1988; 148: 1720–1724.
97. Strausbaugh LJ, Jernigan DB, Liedtke LA. National shortages of antimicrobial agents: Results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network Clin Infect Dis; 2001; 33:1495–1501.
98. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezo-lid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococci: Results from a randomized clinical trial Surgical Infections; 2003; 4:57–70.
99. Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, Crouch CW, Hafkin B, Glick HA. Comparison of length of hospital stay for patients with known or suspected methicillin- resistant Staphylococcus species infections treated with linez- olid or vancomycin: A randomized, multicenter trial Pharmacotherapy; 2001; 21:263–274.
100. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: Analysis of two doubleblind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest; 2003; 124:178–997.
101. Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol; 2003; 6:427–430.